HEMGENIX

Current HCP resources still links the July 2023 patient enrollment form, which specifies this email. Current brand pages corroborate phone and assistance assessment. Financial, travel and copay eligibility are reviewed individually. No enrollment fax is published in the reviewed form.

CSL Case Managers conduct benefits investigation, assess financial assistance and enroll eligible patients in the HEMGENIX copay program. These contacts cover HEMGENIX only; other CSL products have different programs.

Published provider route to request the optional AAV5 NAb test kit and ask about its requisition process. The source explicitly says testing is not an eligibility requirement for HEMGENIX. No laboratory specimen mailing address is inferred.

The currently linked 2023 consent allows cancellation by telephone or written letter. This address is not enrollment or specimen intake. The form’s separate King of Prussia footer is a corporate address.